科笛-B(02487.HK):CU-40102(外用非那雄胺噴霧劑)獲得香港衞生署上市批准
格隆匯8月1日丨科笛-B(02487.HK)公吿,集團的CU-40102(外用非那雄胺噴霧劑)已獲得中國香港特別行政區政府衞生署上市批准,獲批的適應症為治療雄激素性脱髮。這是CU-40102繼取得中國國家藥品監督管理局上市批准後又一重大進展。
非那雄胺作為特異性II型5α-還原酶競爭抑制劑抑制頭皮中睾酮轉化為雙氫睾酮,可治療雄激素性脱髮。與口服非那雄胺不同,CU-40102的外用製劑便於患者將藥物直接精確地塗抹在頭皮表面,與口服藥比較,可降低藥物的全身暴露。集團相信CU-40102作為外用藥將更容易被患者接受,為雄激素性脱髮患者提供一種替代解決方案,成為患者新的用藥選擇。
作為集團於毛髮疾病及護理領域獲得上市批准的重要產品,CU-40102正在中國開展廣泛的商業化準備活動。此次獲批將進一步深化CU-40102的國際化佈局,拓寬CU-40102的市場空間,使更多雄激素性脱髮患者獲益。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.